Table 3.

Comparison of relative fluorescence intensity expressed by the median of P‐glycoprotein with CML status

Relative fluorescence intensity expressed by the median of P‐glycoprotein
CML patients responders VS non‐responders to IM	CML patients achieved VS not achieved their CCyR	CML patients with primary VS secondary resistance to IM	Nilotinib‐treated VS dasatinib‐treated CML patients
0.80 ± 0.09 vs 1.26 ± 0.09; P = .001	1.17 ± 0.03 vs 1.33 ± 0.05; P = .001	1.29 ± 0.08 vs 1.17 ± 0.02; P = .001	1.3 ± 0.07 vs 1.18 ± 0.04; P = .001

Abbreviations: CCyR, complete cytogenetic response IM, imatinib; CML, chronic myeloid leukemia.